{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-017407","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.309030+00:00","generated_at":"2026-06-21T23:36:40.755832+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Gain Therapeutics Q3 net loss $4.56M ($0.38/share); cash $25.7M; CEO promoted; GT-02287 Phase 1 expected mid-2023","bullets":["Net loss of $4.56M ($0.38 per share) vs $4.66M ($0.39) in Q3 2021.","Cash, equivalents, and marketable securities $25.7M, providing runway into Q2 2024.","R&D expenses $1.96M (down 21% YoY); G&A $2.79M (up 27% YoY).","Matthias Alder promoted to CEO and appointed to board of directors.","Lead Parkinson's candidate GT-02287 to commence Phase 1 trial in mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-017407","json":"https://secwatch.observer/filing/0001558370-22-017407.json","markdown":"https://secwatch.observer/filing/0001558370-22-017407.md","text":"https://secwatch.observer/filing/0001558370-22-017407.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000155837022017407/0001558370-22-017407-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000155837022017407/ganx-20221110x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:36:40.755832+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"11fac9a18e7a80d83a6bca3f2affab7046532031","claim":"Gain Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 10, 2022, Gain Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2022, and business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819411/000155837022017407/0001558370-22-017407-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}